Retroductal gene delivery systems - Genteric

Drug Profile

Retroductal gene delivery systems - Genteric

Alternative Names: MnSOD therapy; Retroductal gene delivery systems

Latest Information Update: 08 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genteric
  • Class Gene therapies
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Haemophilia A; Haemophilia B; Hepatitis C

Most Recent Events

  • 13 Aug 2003 Preclinical trials in Hepatitis C in USA (unspecified route)
  • 28 May 2001 Preclinical development for Gaucher's disease in USA (Unknown route)
  • 28 May 2001 Preclinical development for Haemaphilia B in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top